Nimacimab P1b Safety and Tolerability Data
Related Documents:
EASD Medical Conference Presentation of P1b Data for Nimacimab
At EASD 2025, Skye presented an assessment of the safety, tolerability, and pharmacokinetics of nimacimab after repeat dosing in subjects with metabolic associated steatotic liver disease (MASLD).